1.1151.76% ( -0.020 )
Delay Closed: Nov 13, 16:08:17Valuation
Current ValuationThe current P/E ratio is -4.83, within the reasonable range, cheaper than 75.77% of the time in the past 5 years, and the industry ranks 41/53, the industry Median 6.78.
-4.83xP/E
HK$1.12Stock price
HK$-0.23Earnings per share
-4.83xP/E
Stock priceHK$1.12Earnings per shareHK$-0.23
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 11.89x
- Typical range
- -5.93x–19.97x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 6.78x
010203040
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 6.78x
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
06887HKSUNSHINE PHARMA | -64.25x | -- | HK$21.08B |
02630HKVIGONVITA-B | -34.51x | -- | HK$12.11B |
09637HKALEBUND-B | -8.85x | 48.51% | HK$7.17B |
00570HKTRAD CHI MED | -4.83x | 223.71% | HK$5.61B |
02575HKXUANZHUBIO-B | -17.71x | -- | HK$4.28B |
01477HKOCUMENSION-B | -28.07x | 52.83% | HK$4.06B |
01349HKFUDANZHANGJIANG | -20.20x | -- | HK$2.43B |
02552HKHUA MEDICINE-B | -18.52x | 104.78% | HK$2.30B |
02652HKCF PHARMTECH | -267.18x | -- | HK$2.09B |
06622HKZHAOKE OPHTH-B | -4.81x | -- | HK$1.19B |
01652HKFUSEN PHARM | -248.88x | -- | HK$665.37M |
01011HKNT PHARMA | -10.92x | -- | HK$346.74M |
01643HKMODERN CHI MED | -6.04x | -- | HK$291.60M |
00575HKREGENT PACIFIC | -16.12x | -- | HK$246.58M |
08329HKNEP INTERLONG | -3.40x | -- | HK$206.39M |
00455HKTIANDA PHARMA | -2.24x | -- | HK$154.80M |
00858HKEXTRAWELL PHAR | -0.16x | -- | HK$153.70M |
01312HKKONTA CHINA | -0.71x | -- | HK$150.89M |
01498HKPURAPHARM | -4.26x | -- | HK$117.90M |
01889HKSANAI HEALTH GP | -1.01x | -- | HK$22.63M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
